SI-BONE, Inc. (SIBN) has a MoatMap StockRank of 45/100 based on Quality (54/100), Value (43/100), and Momentum (35/100) factor scores. The current signal is HOLD. SI-BONE is a medical device company focused on joint fusion. While it has a niche product, it lacks the broad macro tailwinds of our core themes and does not possess the established profitability or capital-return profile of a high-quality compounder.
SI-BONE is a leading medical device company pioneering minimally invasive surgical solutions for joint dysfunction in the sacroiliac (SI) joint, sacrum, and pelvis. The company's flagship iFuse Implant System is backed by an extensive body of clinical evidence, making it the gold standard for SI joint fusion procedures. Its competitive moat is secured by robust patent protection, exclusive surgeon training programs, and favorable reimbursement coverage from major insurance payors.
| Price | $15.53 |
| Market Cap | $639M |
| P/E (Forward) | -42.17 |
| Price/Book | 3.68 |
| Return on Equity | -9.6% |
| Return on Invested Capital | -7.6% |
| Debt/Equity | 24.00 |
| Gross Margin | 79.6% |
| Operating Margin | -9.7% |
| Revenue Growth | 11.2% |
| Free Cash Flow | $-3M |
SI-BONE, Inc. operates in the Medical Devices industry, part of the Healthcare sector (United States).